Free Trial

Cogent Biosciences Q2 2024 Earnings Report

Cogent Biosciences logo
$7.84 +0.04 (+0.51%)
(As of 12/20/2024 05:51 PM ET)

Cogent Biosciences EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.56
Beat/Miss
Missed by -$0.03
One Year Ago EPS
-$0.59

Cogent Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cogent Biosciences Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry. 

Cogent Biosciences Earnings Headlines

HC Wainwright Has Negative Forecast for COGT FY2024 Earnings
Amazon coin set to soar 25X – starting December 16th?
This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024
See More Cogent Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email.

About Cogent Biosciences

Cogent Biosciences (NASDAQ:COGT), a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

View Cogent Biosciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings